Navigation Links
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
Date:7/22/2013

Call
At 8:30 a.m. Eastern Time today, July 22, 2013, Isis will conduct a live webcast and slide presentation conference call to discuss the positive Phase 2 data.  Interested parties may listen to the call by dialing 866-652-5200, or access the webcast with or without audio at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the discovery, development, and potential of drugs for cardiovascular diseases, and the development, activity, therapeutic potential and safety of ISIS-APOCIIIRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeut
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... MENLO PARK, Calif. , Sept. 2, 2015 ... company today announced that Jim Pekarsky , chief executive ... & Renshaw 17th Annual Global Investment Conference taking place, September ... York . Mr. Pekarsky is scheduled to ... in Astor Suite A (2 nd floor). ...
(Date:9/2/2015)... MENLO PARK, Calif. , Sept. 2, ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... cancer therapies, today announced that it will present ... Mechanisms and Cytotoxic Activity of Dianhydrogalactitol (VAL-083) to ... Mutant p53," at the American Association for ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of the "Pharmaceutical Regulatory ... - October 18-19, 2015)" conference to their ... Compliance with Regulatory Requirements Particularly relevant ... and Document Management Functions & Regulatory Authorities ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4Pharmaceutical Regulatory Affairs Course in the Middle East, Dubai (Dubai, UAE - October 18-19, 2015) 2
... in CA, FL, IN, ME, NC, NY, SC, VT ... and enhance,prevention, self-management of health conditions, PRINCETON, N.J., ... today during a telenews conference the,first round of grants ... $2 million in grants will enable 12 research teams ...
... First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell Transplant in ... Over a Decade -, - ... ... Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase 3 study of ...
Cached Medicine Technology:Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 2Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 3Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 4Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 5Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 6Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 7Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S. 8ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6
(Date:9/2/2015)... Las Vegas, NV (PRWEB) , ... September 02, ... ... Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an ... largest medical auction house in the world, selling more than 100,000 pieces of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 2015 , ... Please join the world renowned Brain Aneurysm ... established by the Foundation in 2007 with the help of Massachusetts State Representative ... remains our top priority,” commented Christine Buckley, Executive Director of the Brain Aneurysm ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit focused on ... will launch Act On Facts, a campaign to educate women to be breast ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 ... of plastic surgeries conducted each year on teenagers, quoting a New York City-area ... Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2
... January 12, 2010 (BRONX, NY) Older women ... lesions that cause dementia later in life, according to ... The findings were published in the December 2009 online ... The research was conducted as part of the ...
... WINSTON-SALEM, N.C. A fast-acting compound that appears to ... found in patients with progressive Alzheimer,s disease has been ... Medicine and the Vanderbilt University Medical Center Program in ... result in humans. The compound benzylquinolone carboxylic ...
... ... Molecular Medicine. Molecular Medicine publishes research concerned with the pathogenesis of disease at the ... prevention. , ... January 12, 2010 -- By the time a person experiences symptoms of an aggressive ...
... , DETROIT , Jan. 12 ... Board of Directors has set the date for the Company,s Annual Meeting ... vote at the meeting.   , The Annual Shareholders, Meeting will be ... EST at the MGM Grand Hotel, 1777 Third Street in ...
... hospice and preferred place of death are often needed, experts ... patients have much to consider, from whether they want to ... want doctors to continue aggressive treatment or focus on making ... those difficult, emotional conversations aren,t happening nearly as often, or ...
... WASHINGTON , Jan. 12 The American Lung ... report, which grades the strength of federal and state ... at the heart of America,s chronic disease crisis. , The ... still has significant room for progress. Most state governments , ...
Cached Medicine News:Health News:Hypertension linked to dementia in older women 2Health News:Hypertension linked to dementia in older women 3Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 2Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 3Health News:News from the Latest Issue of Molecular Medicine 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 3Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 2Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 2Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 4Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 5Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 6Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 7Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 8
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: